尼妥珠单抗联合同步放化疗治疗晚期食管癌的疗效与安全性的系统评价

A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

目的分析尼妥珠单抗注射液联合同步放化疗治疗晚期食管癌的临床疗效。方法检索知网、万方、维普、中国生物医学(CBM)、PubMed、Cochrane Library、Wiley Online Library和谷歌学术等数据库,检索尼妥珠单抗联合同步放化疗(试验组)与同步放化疗(对照组)治疗晚期食管癌的随机对照试验(RCT)。应用Rev Man5.3软件分析组间客观缓解率(ORR)、疾病控制率(DCR)以及药物的相关不良反应发生率的差异。结果最终纳入9项研究,其中有8项为中文研究,1项为外文研究。Meta分析结果显示,试验组患者ORR、DCR显著改善且不会增高不良反应的发生率。结论尼妥珠单抗注射液联合同步放化疗的疗效及用药安全性值得肯定,治疗过程中可能出现皮疹及血压变化,但概率较低、程度较轻。

Objective To analyze the clinical effect of nitorzumab injection combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer.Methods The databases such as CNKI,Wanfang,VIP,China Biology Medicine(CBM),PubMed,Cochrane Library,Wiley Online Library and Google Academic were searched.The randomized controlled trials(RCT)of nituozumab combined with concurrent chemoradiotherapy(experimental group)and concurrent chemoradiotherapy(control group)were searched.The between-group differences of objective remission rate(ORR),disease control rate(DCR)and drug-related adverse reactions were analyzed by RevMan5.3 software.Results Totally 9 studies were included,in which 8 studies were Chinese literatures and one study was foreign language literature.Meta-analysis showed that the ORR and DCR of the experimental group significantly improved and the incidence of adverse reactions was not increased.Conclusion Efficacy and safety of nituozumab injection combined with concurrent chemoradiotherapy are reliable and definite.Rash and change of blood pressure may appear in the course of treatment,but the probability and the degree are relative low.